312:
25:
578:
277:
and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of
297:
In
February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd (SYB). The agreement gives SYB the right to register, manufacture and market the product in China.
392:
cells. HCC is one of the most common cancers worldwide and late stage HCC has a mean overall survival of only 9–11 months on the best available treatment today. Medivir motivated the transition from its origin in
376:, where existing therapies are not very successful and there is a great opportunity to provide real benefit to patients who have few treatment options. Some cancer types of particular interest to Medivir include
474:
526:
129:
388:, which are all highly aggressive diseases with poor treatment options and very low overall survival rates on the best current treatments today. HCC is a liver cancer derived from
649:
664:
644:
639:
527:"Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear® in China"
615:
89:
659:
359:
279:
108:
341:
61:
654:
337:
68:
46:
411:
75:
608:
157:
415:
397:
to oncology by it being a logical extension of their expertise in liver disease from earlier work on
57:
377:
333:
322:
42:
381:
326:
35:
634:
139:
601:
8:
385:
82:
450:
291:
589:
394:
585:
437:
422:
628:
475:"Swedish pharma firm Medivir partners Aragen Life Sciences for drug research"
167:
153:
147:
433:
398:
373:
372:
In 2016 Medivir announced that it would focus its research on cancers of
128:
389:
287:
283:
550:
311:
24:
426:
274:
195:
270:
577:
455:
500:
258:
49:. Unsourced material may be challenged and removed.
626:
273:company. Medivir focuses its research focus on
609:
650:Biotechnology companies established in 1988
404:
340:. Unsourced material may be challenged and
616:
602:
127:
584:This corporation or company article is a
360:Learn how and when to remove this message
109:Learn how and when to remove this message
627:
665:Companies listed on Nasdaq Stockholm
572:
338:adding citations to reliable sources
305:
47:adding citations to reliable sources
18:
645:Companies based in Stockholm County
13:
640:Pharmaceutical companies of Sweden
14:
676:
576:
310:
23:
34:needs additional citations for
551:"Medivir portfolio on website"
543:
519:
493:
467:
1:
461:
16:Swedish biotechnology company
588:. You can help Knowledge by
7:
444:
301:
290:. Medivir is listed on the
179:; 36 years ago
10:
681:
571:
416:Cutaneous T cell lymphoma
254:
244:
233:
225:
212:
202:
191:
173:
163:
145:
135:
126:
660:Drug discovery companies
405:Notable ongoing projects
378:hepatocellular carcinoma
382:glioblastoma multiforme
374:high unmet medical need
655:Life sciences industry
282:and in the science of
140:Public limited company
334:improve this section
43:improve this article
280:protease inhibitors
246:Number of employees
229:Oncological R&D
123:
479:The Economic Times
121:
597:
596:
501:"Medivir website"
386:pancreatic cancer
370:
369:
362:
264:
263:
240:
221:
119:
118:
111:
93:
672:
618:
611:
604:
580:
573:
567:
566:
564:
562:
547:
541:
540:
538:
537:
523:
517:
516:
514:
512:
497:
491:
490:
488:
486:
471:
451:Fast track (FDA)
395:retroviral drugs
365:
358:
354:
351:
345:
314:
306:
292:Nasdaq Stockholm
238:
219:
187:
185:
180:
154:Nasdaq Stockholm
131:
124:
120:
114:
107:
103:
100:
94:
92:
51:
27:
19:
680:
679:
675:
674:
673:
671:
670:
669:
625:
624:
623:
622:
570:
560:
558:
549:
548:
544:
535:
533:
525:
524:
520:
510:
508:
499:
498:
494:
484:
482:
473:
472:
468:
464:
447:
407:
366:
355:
349:
346:
331:
315:
304:
259:www.medivir.com
247:
215:
205:
183:
181:
178:
150:
115:
104:
98:
95:
52:
50:
40:
28:
17:
12:
11:
5:
678:
668:
667:
662:
657:
652:
647:
642:
637:
621:
620:
613:
606:
598:
595:
594:
581:
569:
568:
542:
518:
492:
481:. 16 July 2015
465:
463:
460:
459:
458:
453:
446:
443:
442:
441:
438:osteoarthritis
436:inhibitor for
430:
419:
412:HDAC inhibitor
410:Remetinostat,
406:
403:
401:to this area.
368:
367:
318:
316:
309:
303:
300:
294:Mid Cap List.
262:
261:
256:
252:
251:
248:
245:
242:
241:
235:
231:
230:
227:
223:
222:
216:
213:
210:
209:
206:
203:
200:
199:
193:
189:
188:
175:
171:
170:
165:
161:
160:
151:
146:
143:
142:
137:
133:
132:
117:
116:
31:
29:
22:
15:
9:
6:
4:
3:
2:
677:
666:
663:
661:
658:
656:
653:
651:
648:
646:
643:
641:
638:
636:
635:Company stubs
633:
632:
630:
619:
614:
612:
607:
605:
600:
599:
593:
591:
587:
582:
579:
575:
574:
557:. 25 May 2018
556:
552:
546:
532:
528:
522:
507:. 1 June 2015
506:
502:
496:
480:
476:
470:
466:
457:
454:
452:
449:
448:
439:
435:
431:
428:
427:solid tumours
424:
420:
417:
413:
409:
408:
402:
400:
396:
391:
387:
383:
379:
375:
364:
361:
353:
343:
339:
335:
329:
328:
324:
319:This section
317:
313:
308:
307:
299:
295:
293:
289:
285:
281:
276:
272:
269:is a Swedish
268:
260:
257:
253:
249:
243:
236:
232:
228:
224:
218:Uli Hacksell
217:
211:
207:
201:
197:
194:
190:
176:
172:
169:
168:Biotechnology
166:
162:
159:
155:
152:
149:
144:
141:
138:
134:
130:
125:
113:
110:
102:
91:
88:
84:
81:
77:
74:
70:
67:
63:
60: –
59:
55:
54:Find sources:
48:
44:
38:
37:
32:This article
30:
26:
21:
20:
590:expanding it
583:
559:. Retrieved
554:
545:
534:. Retrieved
530:
521:
509:. Retrieved
504:
495:
483:. Retrieved
478:
469:
423:SMAC mimetic
421:Birinapant,
371:
356:
347:
332:Please help
320:
296:
266:
265:
192:Headquarters
136:Company type
105:
96:
86:
79:
72:
65:
53:
41:Please help
36:verification
33:
511:13 December
434:Cathepsin K
399:hepatitis C
288:nucleosides
284:nucleotides
237:658 MM SEK
204:Area served
629:Categories
536:2020-02-25
485:1 December
462:References
390:hepatocyte
384:(GBM) and
214:Key people
122:Medivir AB
69:newspapers
350:June 2021
321:does not
148:Traded as
58:"Medivir"
531:BioSpace
445:See also
432:Miv-711
302:Oncology
275:oncology
226:Products
198:, Sweden
196:Huddinge
164:Industry
99:May 2018
555:Medivir
505:Medivir
380:(HCC),
342:removed
327:sources
271:biotech
267:Medivir
255:Website
234:Revenue
182: (
174:Founded
156::
83:scholar
561:25 May
239:(2015)
208:Global
158:MVIR B
85:
78:
71:
64:
56:
456:MALT1
220:(CEO)
90:JSTOR
76:books
586:stub
563:2018
513:2016
487:2016
425:for
414:for
325:any
323:cite
286:and
184:1988
177:1988
62:news
336:by
45:by
631::
553:.
529:.
503:.
477:.
250:15
617:e
610:t
603:v
592:.
565:.
539:.
515:.
489:.
440:.
429:.
418:.
363:)
357:(
352:)
348:(
344:.
330:.
186:)
112:)
106:(
101:)
97:(
87:·
80:·
73:·
66:·
39:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
